The Professional Home for Oncology Nurses

Ensuring staff have access to information in their cancer center is the number one facilitator in implementing cancer survivorship exercise programs, researchers reported in the January 2026 issue of the Journal of Cancer Survivorship. Other characteristics of cancer centers, such as ease of referral processes and resources, are also common facilitators.

In oncology, language matters. The words we use to describe illness, treatment, and death shape how patients understand their experience—and how families carry it forward. Few phrases are more deeply ingrained in cancer culture than the idea of fighting cancer, of winning or losing a battle. Although those metaphors may resonate for some, they can unintentionally cause harm when cancer becomes terminal.

From TIME.com: Pancreatic cancer is one of the most challenging diseases to treat, and while survival rates have improved since the 1970s, they have plateaued in recent years. But two promising drugs in the pipeline each seem to double survival.

Revolution Medicines reported on April 13 that its cancer pill, daraxonrasib, helped patients survive an average of 13.2 months after starting treatment, compared to 6.7 months for those receiving standard chemotherapy. “These are dramatic results, with practice-changing outcomes,” says Dr. Mark Goldsmith, CEO of Revolution Medicines, in an interview with TIME.

The following day, research supported by another company, Actuate Therapeutics, was published in Nature Medicine showing that the company’s pancreatic cancer drug, elraglusib, also doubled one-year survival for patients taking it compared to those getting standard chemotherapy. Elraglusib is given by IV.

On May 8, 2026, the U.S. Food and Drug Administration (FDA) approved zenocutuzumab-zbco (Bizengri^®) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. 

Have you kept an eye on ONS Voice’s latest oncology drug reference sheets? Check your memory for the answer to our quick quiz.

What is the hype around bispecific antibodies (BsAbs)? Why are they so much cooler than the monoclonal antibodies? What are they used for? How are they administered? What do oncology nurses administering BsAbs need to know? These are the questions that I used to wonder about when I first heard about this drug class. BsAbs are the popular new kid on the block, and there is so much more that we need to learn about this kid.